DailyIQ
|
DailyIQ
|
Sector:HealthcareAll sectors
Last updated1 minute ago

RPRX·Royalty Pharma plc

$67.90
+0.33 (+0.49%)
High
$68.15
Open
$66.42
Market Cap
39.22B
52W High
$69.77
Low
$66.42
P. Close
$67.90
P/E
48.13
52W Low
$37.31
Fwd P/E
11.63
DailyIQ Est.
$66.44
Inst. Own.
23.6%
Short Interest
2.22%
Days to Cover
4.3
Div. Yield
1.37%
Next Ex-Div
~Nov 13
NewEarnings release, scored · filed Nov 4, 2026tone -6.3 vs prior release · 148 lines scoredSee the breakdown
Technical Score (1D)
87
BULLISH
News Sentiment
58
BULLISH
On Nov 6, analysts reported that Royalty Pharma’s share price had risen 168 % over the past three years, raising questions about whether the current valuation is justified by earnings. The company’s model of collecting royalties from a broad portfolio of blockbuster drugs offers more stable revenue than a single‑product biotech, yet the rapid price climb has strained the earnings‑to‑price ratio. Analysts compared the stock to a fair‑value benchmark and suggested that the market may be overpaying for the royalty collector’s earnings potential. On Nov 5, Royalty Pharma increased its 2026 full‑year guidance for the third consecutive quarter after reporting higher portfolio receipts and securing new royalty agreements on Zoryve and Mimrylo. The company also highlighted positive milestones in its pipeline, reinforcing expectations of continued growth. These developments have driven a strong year‑to‑date share price gain of nearly 74 %, suggesting that the market is pricing in the upgraded outlook. The guidance lift, coupled with new royalty deals, positions RPRX favorably within the royalty and healthcare cash‑flow sector.
LOW TARGET
$61 -10.2%
2 analysts
MEAN TARGET
$65 -3.7%
6 analysts
HIGH TARGET
$70 +3.1%
8 analysts
PRICE RANGE
$61.00 - $70.00
SB / B / H / S / SS
4/9/1/1/1
DAILYIQ EST.
$66.44 (-2.2%)
Sector
Healthcare
Industry
Biotechnology
Exchange
NMS
Country
United States
Website
royaltypharma.com
Symbol
RPRX
Description
Royalty Pharma is a specialized investment firm focused on the biopharmaceutical sector, primarily operating within the United States. The company's core business revolves around acquiring royalty interests in marketed drugs and providing funding for the development of innovative therapies. This strategy grants Royalty Pharma exposure to a diversified portfolio, currently encompassing royalties from approximately 35 marketed therapies and 14 development-stage product candidates. These assets span a range of therapeutic areas, including oncology, rare diseases, and infectious diseases, among others. Established in 1996, Royalty Pharma's headquarters are located in New York, positioning it at the heart of the biopharmaceutical industry.
Bought (1Y)
0 shares
$0
Sold (1Y)
612,263 shares
$34.6M
Urist MarshallEVP, Research & Investments
Sell4,126 shares2026-10-05
Bassler Bonnie L-
Award/Grant642 shares2026-09-30
Urist MarshallEVP, Research & Investments
Sell4,126 shares2026-09-28
Hite ChristopherEVP & Chairman, Partnering
Sell3,927 shares2026-09-22
Hite ChristopherEVP & Chairman, Partnering
Sell96,073 shares2026-09-22
View full insider trading history →
69/ 100
Bullish
Overall: Bullish
✓Revenue growing year over year
✓Positive net margin
✓Positive operating cash flow
Net Margin
32.4%
Revenue CAGR
4.1%
Current Ratio
2.40x
Debt / Equity
0.92x
Return on Equity
7.9%
View full financials →
Earnings Summary
In Q4 2024, Royalty Pharma reported EPS of $1.1511 versus an estimate of $1.05403, with revenue of $742 million, indicating a modest earnings beat and solid revenue base. The following year, Q4 2025 saw EPS rise to $1.46 against an estimate of $1.15, while revenue of $874 million exceeded the $859 million forecast, reflecting continued acceleration in both earnings and top line. However, Q1 2026 presented a reversal: EPS of $1.30 fell short of the $1.2368 estimate, and revenue dropped sharply to $925 million from an estimated $1.26 billion, suggesting a significant contraction in revenue growth. Q2 2026 rebounded with EPS of $1.3214 beating the $1.27238 estimate and revenue of $773 million surpassing the $707 million forecast, while Q3 2026 maintained EPS near estimate at $1.21 versus $1.2053 and revenue of $890 million beating the $812 million estimate. This pattern shows a volatile revenue trajectory with earnings generally meeting or exceeding expectations, except for the Q1 2026 dip. Historically, Royalty Pharma has delivered YoY revenue growth in most quarters, with notable EPS beats in Q4 2024, Q4 2025, Q2 2026, and Q3 2026, underscoring a trend of earnings resilience amid revenue swings. Recent news highlights a Q3 2026 earnings beat and a full-year revenue guidance of $3.5–$3.55 billion, reinforcing investor confidence. The key will be whether the company can sustain its earnings momentum while stabilizing revenue growth in the next quarter.

EPS

EstBeatMiss
$0.98$1.14$1.30$1.47$1.63Q4'24Q4'25Q1'26Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$1.55 - -
Q3'26$1.21$1.21+0.4%
Q2'26$1.27$1.32+3.9%
Q1'26$1.24$1.30+5.1%
Q4'25$1.15$1.46+27.0%
Q4'24$1.05$1.15+9.2%

Revenue

EstBeatMiss
$624M$804M$983M$1.2B$1.3BQ4'24Q4'25Q1'26Q2'26Q3'26Q4'26
QtrEstActual+/−
Q4'26$869M - -
Q3'26$812M$890M+9.5%
Q2'26$707M$773M+9.3%
Q1'26$1.3B$925M-26.6%
Q4'25$859M$874M+1.7%
Q4'24 - $742M -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

RPRX Stock Snapshot

BULLISH87/100
$67.90+$0.33 (0.5%)
Market cap
39.22B
P/E ratio
48.1
Day range
$66.42 – $68.15
News sentiment
58/100 · Neutral
Analyst target
$65.38 (-3.7%)
Consensus
Buy · 16 analysts
52-week range+82.0% off low · -2.7% from high
$37.31$69.77
Price $67.90 DailyIQ Est. $66.44

Momentum is working in RPRX's favour - it ranks in the upper part of DailyIQ's momentum universe. The stock is liquid enough that positioning changes get absorbed without distorting the trend.

Behaviour On Record

What RPRX's own history says about today's numbers

Realized volatility (21d)
25.4% 40th pct
Below its peak
0.0%
vs 200-day average
+26.1%
Up days (1y)
51%

Royalty Pharma plc is currently running 25.4% annualised volatility over the last 21 sessions. Measured against RPRX's own 6 years of daily returns rather than a market-wide average, that is the 40th percentile — on the quiet side for this stock, against a typical reading of 27.4%.

RPRX is at its running peak. Across 6 full years on file its median worst-drawdown-in-a-year was -18.7%, with the deepest at -34.1% in 2023.

Price sits +26.1% from its 200-day moving average. Against every other day in its history, that gap ranks at the 96th percentile — a wider gap than this stock usually carries. Over the past year RPRX closed higher on 51% of sessions, and it is currently 1 session into a rising streak.

On November specifically: over 6 years of records, RPRX finished the month higher 5 of 6 times, with a median return of +2.6% and an average of +4.1%. Its strongest month historically has been January at +5.3% on average, its weakest September at -3.6%.

Overnight risk is measurable too: RPRX has opened more than 2% away from the prior close in 142 of 1,606 sessions (8.8% of the time), with the largest gaps running +8.0% and -6.3%.

Across the last 3 dated reports on file, RPRX moved an average of 0.7% in the session after earnings, closing higher 1 of those 3 times, with a median move of -0.4% and a largest of +1.2%.

All figures computed from 1,607 daily closes between 2020-06-16 and 2026-11-04, split-adjusted, recomputed daily. Percentiles are against RPRX's own 6-year history, not a peer group or index.

Sector Rotation

Is money rotating into or out of RPRX's sector?

Royalty Pharma plc sits in the Health Care sector, currently ranked 1st of 12 GICS sectors by relative-strength rotation score (weakening). Within its narrower Biotechnology industry group, RPRX ranks 7th of 15 tracked industries, weakening.

Sector rank
#1 of 12
Sector state
Weakening
Sector rotation score
100
Industry rank
#7 of 15

Options Market

What is the options market pricing for RPRX?

CallsPuts

For Royalty Pharma plc's nearest expiry (2026-11-20, 14 days out), open interest is call-heavy, a bullish tilt (put/call ratio of 0.32), with at-the-money implied volatility around 41.9%. The options market is pricing roughly a ±13.2% move by that expiry — a range of about $58.91–$76.77.

Put/call ratio (2026-11-20)
0.32
ATM implied volatility
41.9%
Total open interest
363
Expected move by 2026-11-20
±13.2% ($58.91–$76.77)

Analyst Consensus Estimates

What do analysts expect RPRX to earn?

Analysts expect Royalty Pharma plc to earn $5.32 per share in the fiscal year ending Dec 2026 and $6.26 in the fiscal year ending Dec 2028, from 2 estimates. These are analyst forecasts, not company guidance, and later years rest on fewer analysts.

Quarter endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Sep 2026$1.18$1.15 to $1.226$885M4
Dec 2026$1.52$1.39 to $1.635$942M3
Fiscal year endingEPS estimateEPS rangeEPS analystsRevenue estimateRevenue analysts
Dec 2026$5.32$5.17 to $5.446$3.51B5
Dec 2027$5.81$5.31 to $6.236$3.82B5
Dec 2028$6.26$6.00 to $6.522~$4.24B-

Revenue marked ~ is our calculation from the EPS estimate, not analyst consensus.

Analyst Rating Changes

Are analysts turning bullish or bearish on RPRX?

Morgan Stanley most recently reiterated its rating on Royalty Pharma plc to Overweight on Oct 7, 2026 with a price target of $67 (from $65). Over the last 90 days, coverage has run 0 upgrades against 0 downgrades, a net mixed lean.

Latest action
Morgan Stanley: Overweight
90-day upgrades
0
90-day downgrades
0
Net rating momentum
0
DateFirmActionRatingPrice target
Oct 7, 2026Morgan StanleyMaintainedOverweight$65 → $67
Sep 8, 2026TD CowenMaintainedBuy$65 → $68
Aug 7, 2026JP MorganMaintainedOverweight$58 → $62
Jul 13, 2026TD CowenMaintainedBuy$50 → $65
May 7, 2026CitigroupMaintainedBuy$50 → $66
May 7, 2026JP MorganMaintainedOverweight$50 → $58
Apr 21, 2026UBSMaintainedBuy$51 → $57
Apr 10, 2026Morgan StanleyMaintainedOverweight$61 → $63
Jan 30, 2026UBSUpgradeNeutral → Buy$38 → $49
Jan 27, 2026CitigroupMaintainedBuy$48 → $50
Dec 11, 2025TD CowenMaintainedBuy$42 → $45
Oct 10, 2025Morgan StanleyMaintainedOverweight$55 → $54

Earnings Release, Scored

What did Royalty Pharma plc's latest earnings release say?

Filed Nov 4, 2026 · SEC Form 8-K, Exhibit 99

Tone58.1/ 100-6.3 vs prior release
Hedging words0.83per 100 words+0.07 vs prior release
Tone, last 3 releasesScale 50–70

Most important lines

  1. 1

    Lastly, we remain excited by the potential for R&D co-funding with global biopharma - where we have announced $1 billion of transactions so far this year - which represents an important new opportunity for our business.

    New this quarter
  2. 2

    ImdelltraIn September 2026, Amgen announced positive results from the Phase 3 DeLLphi-305 study of Imdelltra in combination with Imfinzi as first-line maintenance treatment for extensive-stage small cell lung cancer.

    New this quarter
  3. 3

    TEV-’408In September 2026, Teva announced positive topline results from an ongoing Phase 2a study of TEV-’408, an anti-IL-15 antibody, in adults with celiac disease.

    New this quarter

Scores describe the release's wording. They are not a forecast.

Read all 148 scored lines →

Peers & ETF holders

RPRX peers & ETF holders

BiotechnologyMarket cap · today

Top ETF holdersWeight

News & sentiment

What is the news saying about RPRX?

RPRX rose 19.7% over the month to Nov 6. News tone held between 50 and 72 from Oct 7 to Oct 9, then jumped to 92 on Oct 12.

Daily close and news tone, Oct 6 to Nov 6
$55$60$65Oct 6Oct 7: tone 70Oct 8: tone 73Oct 9: tone 50Oct 12: tone 92Oct 13Oct 14Oct 15: tone 71Oct 16: tone 58Oct 19Oct 20Oct 21Oct 22: tone 57Oct 23Oct 26Oct 27Oct 28: tone 71Oct 29: tone 60Oct 30: tone 57Nov 2Nov 3: tone 52Nov 4: tone 69Nov 5: tone 82Nov 6: tone 62Oct 6News toneNov 6123
  1. Oct 14 +4.9%
  2. Oct 20 +3.3%
  3. Oct 22 +2.6%same day: 3 Reasons Royalty Pharma Is a Dividend Stock You Never Have to Sell
Latest stories naming Royalty Pharma

Technical analysis

How strong is RPRX's momentum right now?

On the daily chart RPRX ranks at the 87th percentile for momentum against 1,060 stocks and ETFs, a bullish reading.

Momentum rank by timeframe0 = weakest, 100 = strongest
See what drives the rankThe inputs behind each timeframe's momentum rank, plus RSI, stochastics, Bollinger Bands and moving averages. Free with an account.

Institutional ownership

Are big funds buying or selling RPRX?

85 of the 145 tracked managers added to RPRX in their latest 13F and 54 trimmed. Together they own 23.6% of the company, worth $7.7B. Capital International Investors and State Street alone hold 8.2%.

85adding54trimming6unchanged
Largest holders by stake, latest 13FBar = share of RPRX
  1. 1Capital International Investors6.09%
    $2.0B positionAdded 0.8% last quarter
  2. 2State Street Corp2.13%
    $691.8M positionAdded 12.3% last quarter
  3. 3Swedbank AB1.77%
    $598.8M positionTrimmed 4.3% last quarter
  4. 4Vanguard Capital Management LLC0.83%
    $270.6M positionAdded 6.5% last quarter
  5. 5Royal London Asset Management Ltd0.75%
    $242.2M positionAdded 13.4% last quarter
  6. 6Legal & General Group Plc0.66%
    $213.1M positionAdded 13.0% last quarter
  7. 7Amundi0.64%
    $208.8M positionAdded 20.6% last quarter
  8. 8Victory Capital Management Inc0.64%
    $206.5M positionTrimmed 4.4% last quarter
  9. 9UBS Group AG0.54%
    $176.2M positionAdded 73.5% last quarter
  10. 10Charles Schwab Investment Management Inc0.53%
    $172.9M positionAdded 1.8% last quarter
Full holdings history

Discover more

How has RPRX done against its peers?

Over the six months to Nov 6, RPRX returned +34.7%. Of the 15 related stocks and ETFs, 4 did better, led by MRNA at +429.9%.

Change since May 6, through Nov 6
−200%0%+200%+400%+600%May 6JunJulAugSepOctNov 6MRNA +429.9%RPRX +34.7%ALNY −48.3%